X4 Pharmaceuticals (XFOR) Asset Utilization Ratio (2019 - 2025)
X4 Pharmaceuticals (XFOR) reported Asset Utilization Ratio of 0.15 for Q4 2025, up 881.82% on a YoY basis from 0.02 in Q4 2024, and down 38.84% quarter-over-quarter from 0.25 in Q3 2025.
X4 Pharmaceuticals (XFOR) Asset Utilization Ratio (2019 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Asset Utilization Ratio for 4 years, with the latest figure at 0.15 in Q4 2025.
- For the quarter ending Q4 2025, Asset Utilization Ratio rose 881.82% year-over-year to 0.15; the trailing twelve-month figure through Dec 2025 stood at 0.15 (up 881.82% YoY), and the FY2025 full-year result was 0.16, up 823.12% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.15, down from 0.25 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.28 in Q2 2025, with the low at 0.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 0.55 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 0.25 |
| Jun 30, 2025 | 0.28 |
| Mar 31, 2025 | 0.23 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.00 |
| Dec 31, 2020 | 0.02 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.02 |
| Mar 31, 2020 | 0.02 |
| Sep 30, 2019 | 0.03 |